chartexchange

ANAB270115C00055000
ANAB Jan 15 2027 55.00 Call
optionOPRA

EOD
—USD
Loading…
Underlying
Underlying Price
$47.40
Type
Call
Strike
55
Expiration
Jan 15, 2027
DTE
57d
Moneyness
OTM
Intrinsic
$0.00
ANAB 55 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Nov 20, 20261d$47.00+23.07%111
Nov 20, 20261d$0.45-55.00%1147
Dec 18, 202629d$2.60+23.81%115
Jan 15, 202757d——00
Feb 19, 202792d$5.24-41.78%651
May 21, 2027183d$8.00+0.00%22
ANAB Nearby Strikes · Jan 15, 2027
StrikeLastChangeVolOpen IntMoneyness
25 C——00ITM
30 C——00ITM
35 C——00ITM
40 C——00ITM
45 C——00ITM
50 C——00OTM
55 C——00OTM
60 C——00OTM
65 C——00OTM
ANAB Profile

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio's proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c